Wound Management Technologies Announces Jane Fore, MD as Chief Medical Officer and Dr. Alec Hochstein as Medical Directoradmin
ADDISON, TX / ACCESSWIRE / March 19, 2014 / Wound Management Technologies, Inc., (OTCQB: WNDM), announced today that Dr. Jane Fore is the new Chief Medical Officer for the Wound Care Innovations Subsidiary and Dr. Alec Hochstein has joined the company as Medical Director. Both are actively involved in the CellerateRX(R) Activated Collagen product line.
Wound Care Innovations, LLC, has appointed Jane Fore, MD, as Chief Medical Officer for the company. Formerly Medical Director of Wound Care Innovations, Dr. Fore is board certified in internal medicine and hyperbaric medicine and is a fellow of the Academy of Physicians in Wound Healing, being CWS certified since 2003. Dr. Fore has a vast and comprehensive knowledge of wound care treatment practices and has presented at numerous conferences and seminars since 2002 on the topics of hyperbarics, ulcers, wound care, skin protection, diabetic education, and more. She has been actively involved with Wound Care Innovations for over 7 years and has conducted several studies on the efficacy of CellerateRX.
“We are delighted with Dr. Fore’s expanded role with the company”, stated Cathy Bradshaw, President of Wound Care Innovations, LLC. “She is one of the most knowledgeable, experienced, and respected wound care specialists in the industry and brings those attributes to our company.” Dr. Fore added “CellerateRX powder and gel, the patented hydrolyzed Type I collagen, is the product that I use the most in my wound healing practice. Its biocompatibility, adaptability, safety, and effectiveness make it number one in my practice.”
Dr. Alec O. Hochstein is the company’s new Medical Director. Dr. Alec Hochstein has been practicing podiatric medicine for over 17 years. As an astute businessman and clinician, he is also the Founder/COO of Pocket Professions, PC, and the writer and developer of the app, WoundSmart(R) that features CellerateRX. He holds teaching positions at the prestigious residency training programs in New York City and Long Island New York, New York Hospital of Queens, Albert Einstein School of Medicine and North Shore –LIJ Health System. His current practice focuses on his extensive background in diabetic foot care, wound care and reconstructive foot surgery. Hochstein has been actively involved in the research and development of the CellerateRX brand for over 2 years, and has conducted several case studies within his own practice.
“CellerateRX is one of the few products in my career that I feel has truly changed my practice patterns and protocols with respect to healing wounds. I’m happy to be affiliated with a company that will be instrumental in bringing a technology to the market which will enhance the lives of our patients while bringing a cost effective product to the health care system which is facing ever increasing financial scrutiny,” stated Dr. Hochstein. Jennifer Taylor, Director of Marketing and Business Development for Wound Management Technologies added, “Dr. Hochstein brings an unprecedented level of clinical knowledge in both wound care and the surgical environment which is very important to our team at this time. His enthusiasm and passion bring an addition to our team that will go a long way towards strengthening our position in the marketplace and ultimately helping more patients!”
CellerateRX(R) Activated Collagen is the Differentiator
CellerateRX(R)’s Activated Collage(TM) (approximately 1/100th the size of native collagen) delivers the essential benefits of collagen to a wound immediately, where other forms of native, intact collagen in commercially available products require time for the body to break down. In people with compromised health or circulation, the difference in wound healing can be significant. CellerateRX(R) is FDA cleared for all wound types except for 3rd degree burns and is available in both powder and gel form. CellerateRX(R), which has widely been used for treatment of podiatric wounds, specifically diabetic ulcers, is now being utilized by other medical practices. These include but are not limited to the treatment of first and second degree burns, surgical wounds, and dermatological procedures. These additional procedures join the already extensive list of medical conditions CellerateRX(R) has successfully treated.
About Wound Management
Wound Management Technologies, Inc., is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its unique, patented collagen product, CellerateRX(R), which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable hemostat that is in the late stages of development. More information can be found on the company’s web sites: www.wmgtech.com and www.celleraterx.com.
Safe Harbor Statement
The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
Wound Management Technologies, Inc.
16633 Dallas Parkway, Suite 250
Addison, TX 75001
SOURCE: Wound Management Technologies, Inc.
Posted: March 19th, 2014 under ACCESSWIRE.